New phase 2 data from the Dana-Farber study “Phase 2 Trial Shows Deep and Lasting Responses to CAR T-Cell Therapy for High-Risk Smoldering Multiple Myeloma” evaluated Carvykti in high-risk smoldering multiple myeloma — a pre-myeloma setting where the disease is not yet symptomatic, but biologically primed for progression.
CAR-T is moving upstream — and Darzalex-era…
New phase 2 data from the Dana-Farber study “Phase 2 Trial Shows Deep and Lasting Responses to CAR T-Cell Therapy for High-Risk Smoldering Multiple Myeloma” evaluated Carvykti in high-risk smoldering multiple myeloma — a pre-myeloma setting where the disease is not yet symptomatic, but biologically primed for progression.